Exiqon As (EXQNF) 1.5000 $EXQNF
Concise Analysis of the International qPCR and dPCR Instrumentation Market
M2 - Tue Mar 18, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f2m2mm/qpcr_and_dpcr) has announced the addition of the "Concise Analysis of the International qPCR and dPCR Instrumentation Market" report to their offering. This report analyzes the worldwide markets for qPCR and dPCR Instrumentation in US$ Million. The Global market is further analyzed by the following Product Segments and End-Use Markets: Product Segments - qPCR (quantitative Polymerase Chain Reaction), and dPCR (digital Polymerase Chain Reaction); End-Use markets - Educational/Research, Testing Laboratories, and Pharma. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East/Africa, and Latin America. Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 49 companies including many key and niche players such as: - Agilent Technologies - Biofire Diagnostics, Inc. - Bio-Rad Laboratories, Inc. - Cepheid - Eppendorf AG - Exiqon A/S - F. Hoffmann-La Roche Ltd. - Fluidigm Corporation - Illumina, Inc. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. MAJOR TRENDS & ISSUES 3. COMPETITION 4. END-USE MARKET ANALYSIS 5. PRODUCT OVERVIEW 6. INSIGHT INTO GLOBAL SPENDING ON LIFE SCIENCES RESEARCH 7. PRODUCT INNOVATIONS/ INTRODUCTIONS 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. MIDDLE EAST & AFRICA 7. LATIN AMERICA IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 49 (including Divisions/Subsidiaries - 51) - The United States (29) - Canada (1) - Japan (1) - Europe (19) - Germany (7) - The United Kingdom (2) - Spain (1) - Rest of Europe (9) - Asia-Pacific (Excluding Japan) (1) For more information visit http://www.researchandmarkets.com/research/f2...r_and_dpcr
Global MicroRNA Market Report 2013 - Includes Forecasts to 2016
M2 - Fri Dec 20, 9:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/57rqjm/global_microrna) has announced the addition of the "Global MicroRNA Market Report 2013 - Includes Forecasts to 20" report to their offering. One of the most important drivers is the increasing prevalence of diseases such as cancer, which has led to an increase in demand for microRNA-based diagnostic tests. A biomarker is a substance or a molecular or cellular process or event that indicates a biological condition. Several research studies have confirmed that microRNAs have immense potential as biomarkers for a range of diseases, from cancer to cardiovascular diseases. An increasing number of vendors in the market are focusing on the discovery of microRNA biomarkers for diseases that do not as yet have defined microRNA biomarkers. For instance, Biogen Idec Inc., a US-based biotechnology company focusing on the development of drugs for the Healthcare sector, and Regulus Therapeutics Inc., a US-based microRNA therapeutics company, have collaborated in their efforts to discover and develop microRNA biomarkers for multiple sclerosis. Thus, the Global MicroRNA market is witnessing the increasing use of microRNAs as biomarkers. Further, the report states that one of the major challenges in the market is the stringent regulations imposed by the regulatory bodies. Complying with such regulations and obtaining approvals from regulatory authorities is a major challenge for the vendors in this market. The key vendors dominating this market space are: - Alnylam Pharmaceuticals Inc. - Exiqon A/S - Santaris Pharma A/S. Key Topics Covered: 01. Executive Summary 02. Scope of the Report 03. Market Research Methodology 04. List of Abbreviations 05. Introduction 06. Market Landscape 07. Global MicroRNA Research Market 08. Global MicroRNA Market 09. Global MicroRNA Market Segmentation 10. Geographical Segmentation 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/57...l_microrna
Global Companion Biomarkers in Drug Development Market Report 2013
M2 - Tue Dec 17, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/cxq2xl/companion) has announced the addition of the "Global Companion Biomarkers in Drug Development Market Report 2013" report to their offering. "Global Companion Biomarkers in Drug Development Market Report 2013", focuses on companion biomarkers, which are diagnostic tests that are specifically linked to a therapeutic drug either during its development or in the clinic. This linkage can be an important component of the drug development process; alternatively, the companion biomarker can be useful in ameliorating the regulatory process for the drug, or acting as an aid to therapeutic use in the clinic. The report provides market opportunities for companion biomarkers are focused in drug development targets, drug development efficacy and clinical end points in four main therapeutic areas: oncology, cardiovascular, neurology and autoimmune. This analysis also gives insights into the role of companion diagnostic tests in drug development. It provides an in-depth discussion and analysis of the application of companion biomarkers to drug development and targeted therapeutics, as well as their use in clinical trials and the regulatory forum. The examination emphasizes new and developing technology platforms meant to aid in development of drugs for therapeutic use, and sometimes to be available as companion tests for these drugs in the clinic. Key Topics Covered: 1. Overview 2. Introduction: Companion Diagnostics in Drug Development 3. Biomarker Development Tools 4. Market for Biomarkers in Drug Development 5. Imaging Biomarkers in Drug Discovery 6. Clinical Biomarkers Improving Trial Design 7. Biomarkers as Surrogate Endpoints 8. Market Size, Collaborations and Future Directions for Companion Diagnostics in Drug Development 9. Regulatory Issues for Biomarkers in Drug Development 10. Business Decisions Using Companion Biomarkers in Drug Development 11. Company Profiles Companies Mentioned: - Axontologic - Bristol-Myers Squibb Company - Cybrdi - Discerna - Exiqon A/S - Future Diagnostics - Gyros AB - Human Genome Sciences (GSK) - Ipsen - Johnson & Johnson - KOOPrime - Luminex - Multimetrix - Nuvera Biosciences - Oxonica - Pub Gene - Qiagen - Roche - Sygnis Pharma AG - Tyrian Diagnostic - ViaLogy - Wyeth - Zeptosens For more information visit http://www.researchandmarkets.com/research/cxq2xl/companion
Exiqon Awarded Global microRNA Research Tools Company of the Year by Frost & Sullivan
GlobeNewswire - Mon Jul 08, 3:09AM CDT
Exiqon A/S (Copenhagen:EXQ), a leading supplier of high-value products for gene expression analysis, today announced that Frost & Sullivan has recognized Exiqon as the recipient of the 2013 Company of the Year Award in Global microRNA Research Tools in light of the excellence that Exiqon has exhibited in the microRNA research space. This award follows Frost & Sullivan's most recent analysis of the global microRNA research tools and services market.
Molecular Diagnostics in Infectious Disease Testing Report
M2 - Fri Jun 21, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z985r3/molecular) has announced the addition of the "Molecular Diagnostics in Infectious Disease Testing" report to their offering. This report describes the specific segment of the in vitro diagnostics (IVD) market known as molecular diagnostics (MD), with a specialization in the MD tests for infectious disease. In the current medical diagnostics market, molecular diagnostics for infectious disease testing offers one of the brightest areas for growth and innovation. The confluence of breakthroughs in genomics, proteomics, and the development of microarray devices to measure analytes in the blood and various body tissues, has led to this revolutionary market segment offering the power of advanced analytical techniques to the diagnosis and treatment of infectious disease. Continuing new advancements in the ability to detect and diagnose infectious diseases are being made. Whereas before, detection and identification of many clinically import
RNA Interference (RNAi) - Global Strategic Business Report
M2 - Wed Feb 13, 6:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/dqz252/rna_interference) has announced the addition of the "RNA Interference (RNAi) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for RNA Interference (RNAi) in US$ Million by the following Application Areas: Drug Discovery and Target Validation, Reagents, and siRNA Synthesis. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. Key Topics Covered I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Outlook 2. Industry Overview 3. Market Outlook 4. Product Overview 5. Applications O
Concise Analysis of the International qPCR and dPCR Instrumentation Market
M2 - Tue Mar 18, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f2m2mm/qpcr_and_dpcr) has announced the addition of the "Concise Analysis of the International qPCR and dPCR Instrumentation Market" report to their offering. This report analyzes the worldwide markets for qPCR and dPCR Instrumentation in US$ Million. The Global market is further analyzed by the following Product Segments and End-Use Markets: Product Segments - qPCR (quantitative Polymerase Chain Reaction), and dPCR (digital Polymerase Chain Reaction); End-Use markets - Educational/Research, Testing Laboratories, and Pharma. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East/Africa, and Latin America. Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 49 companies including many key and niche players such as: - Agilent Technologies - Biofire Diagnostics, Inc. - Bio-Rad Laboratories, Inc. - Cepheid - Eppendorf AG - Exiqon A/S - F. Hoffmann-La Roche Ltd. - Fluidigm Corporation - Illumina, Inc. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. MAJOR TRENDS & ISSUES 3. COMPETITION 4. END-USE MARKET ANALYSIS 5. PRODUCT OVERVIEW 6. INSIGHT INTO GLOBAL SPENDING ON LIFE SCIENCES RESEARCH 7. PRODUCT INNOVATIONS/ INTRODUCTIONS 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. MIDDLE EAST & AFRICA 7. LATIN AMERICA IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 49 (including Divisions/Subsidiaries - 51) - The United States (29) - Canada (1) - Japan (1) - Europe (19) - Germany (7) - The United Kingdom (2) - Spain (1) - Rest of Europe (9) - Asia-Pacific (Excluding Japan) (1) For more information visit http://www.researchandmarkets.com/research/f2...r_and_dpcr
Global MicroRNA Market Report 2013 - Includes Forecasts to 2016
M2 - Fri Dec 20, 9:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/57rqjm/global_microrna) has announced the addition of the "Global MicroRNA Market Report 2013 - Includes Forecasts to 20" report to their offering. One of the most important drivers is the increasing prevalence of diseases such as cancer, which has led to an increase in demand for microRNA-based diagnostic tests. A biomarker is a substance or a molecular or cellular process or event that indicates a biological condition. Several research studies have confirmed that microRNAs have immense potential as biomarkers for a range of diseases, from cancer to cardiovascular diseases. An increasing number of vendors in the market are focusing on the discovery of microRNA biomarkers for diseases that do not as yet have defined microRNA biomarkers. For instance, Biogen Idec Inc., a US-based biotechnology company focusing on the development of drugs for the Healthcare sector, and Regulus Therapeutics Inc., a US-based microRNA therapeutics company, have collaborated in their efforts to discover and develop microRNA biomarkers for multiple sclerosis. Thus, the Global MicroRNA market is witnessing the increasing use of microRNAs as biomarkers. Further, the report states that one of the major challenges in the market is the stringent regulations imposed by the regulatory bodies. Complying with such regulations and obtaining approvals from regulatory authorities is a major challenge for the vendors in this market. The key vendors dominating this market space are: - Alnylam Pharmaceuticals Inc. - Exiqon A/S - Santaris Pharma A/S. Key Topics Covered: 01. Executive Summary 02. Scope of the Report 03. Market Research Methodology 04. List of Abbreviations 05. Introduction 06. Market Landscape 07. Global MicroRNA Research Market 08. Global MicroRNA Market 09. Global MicroRNA Market Segmentation 10. Geographical Segmentation 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/57...l_microrna
Global Companion Biomarkers in Drug Development Market Report 2013
M2 - Tue Dec 17, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/cxq2xl/companion) has announced the addition of the "Global Companion Biomarkers in Drug Development Market Report 2013" report to their offering. "Global Companion Biomarkers in Drug Development Market Report 2013", focuses on companion biomarkers, which are diagnostic tests that are specifically linked to a therapeutic drug either during its development or in the clinic. This linkage can be an important component of the drug development process; alternatively, the companion biomarker can be useful in ameliorating the regulatory process for the drug, or acting as an aid to therapeutic use in the clinic. The report provides market opportunities for companion biomarkers are focused in drug development targets, drug development efficacy and clinical end points in four main therapeutic areas: oncology, cardiovascular, neurology and autoimmune. This analysis also gives insights into the role of companion diagnostic tests in drug development. It provides an in-depth discussion and analysis of the application of companion biomarkers to drug development and targeted therapeutics, as well as their use in clinical trials and the regulatory forum. The examination emphasizes new and developing technology platforms meant to aid in development of drugs for therapeutic use, and sometimes to be available as companion tests for these drugs in the clinic. Key Topics Covered: 1. Overview 2. Introduction: Companion Diagnostics in Drug Development 3. Biomarker Development Tools 4. Market for Biomarkers in Drug Development 5. Imaging Biomarkers in Drug Discovery 6. Clinical Biomarkers Improving Trial Design 7. Biomarkers as Surrogate Endpoints 8. Market Size, Collaborations and Future Directions for Companion Diagnostics in Drug Development 9. Regulatory Issues for Biomarkers in Drug Development 10. Business Decisions Using Companion Biomarkers in Drug Development 11. Company Profiles Companies Mentioned: - Axontologic - Bristol-Myers Squibb Company - Cybrdi - Discerna - Exiqon A/S - Future Diagnostics - Gyros AB - Human Genome Sciences (GSK) - Ipsen - Johnson & Johnson - KOOPrime - Luminex - Multimetrix - Nuvera Biosciences - Oxonica - Pub Gene - Qiagen - Roche - Sygnis Pharma AG - Tyrian Diagnostic - ViaLogy - Wyeth - Zeptosens For more information visit http://www.researchandmarkets.com/research/cxq2xl/companion
Exiqon Awarded Global microRNA Research Tools Company of the Year by Frost & Sullivan
GlobeNewswire - Mon Jul 08, 3:09AM CDT
Exiqon A/S (Copenhagen:EXQ), a leading supplier of high-value products for gene expression analysis, today announced that Frost & Sullivan has recognized Exiqon as the recipient of the 2013 Company of the Year Award in Global microRNA Research Tools in light of the excellence that Exiqon has exhibited in the microRNA research space. This award follows Frost & Sullivan's most recent analysis of the global microRNA research tools and services market.
Molecular Diagnostics in Infectious Disease Testing Report
M2 - Fri Jun 21, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z985r3/molecular) has announced the addition of the "Molecular Diagnostics in Infectious Disease Testing" report to their offering. This report describes the specific segment of the in vitro diagnostics (IVD) market known as molecular diagnostics (MD), with a specialization in the MD tests for infectious disease. In the current medical diagnostics market, molecular diagnostics for infectious disease testing offers one of the brightest areas for growth and innovation. The confluence of breakthroughs in genomics, proteomics, and the development of microarray devices to measure analytes in the blood and various body tissues, has led to this revolutionary market segment offering the power of advanced analytical techniques to the diagnosis and treatment of infectious disease. Continuing new advancements in the ability to detect and diagnose infectious diseases are being made. Whereas before, detection and identification of many clinically import
RNA Interference (RNAi) - Global Strategic Business Report
M2 - Wed Feb 13, 6:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/dqz252/rna_interference) has announced the addition of the "RNA Interference (RNAi) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for RNA Interference (RNAi) in US$ Million by the following Application Areas: Drug Discovery and Target Validation, Reagents, and siRNA Synthesis. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. Key Topics Covered I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Outlook 2. Industry Overview 3. Market Outlook 4. Product Overview 5. Applications O
